Senti Biosciences Holdings, Inc. SNTI
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Senti Biosciences Holdings, Inc. (SNTI) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to June 30, 2026 it had revenue of $55000 and net income of -$50M, a net margin of -90116.4%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -85%.
About Senti Biosciences
Senti Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $3M in 2021 to $22000 in 2025, a decline of about 70.1% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 761% over three years (dilution for shareholders). It spends 170845% of revenue on research and development.
Score: 0.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $55000 | $22000 | $7M | $3M | $4M | $3M |
| Net income | -$50M | -$61M | -$53M | -$71M | -$58M | -$55M |
| Free cash flow | -$38M | -$44M | -$41M | -$64M | -$76M | -$40M |
| EPS (diluted) | $-1.72 | $-2.73 | $-12.03 | $-16.01 | $-22.30 | $-190.00 |
| Net margin | -90116.4% | -279300.0% | -798.9% | -2774.6% | -1358.1% | -2003.6% |
| ROIC | — | -157.6% | -81.5% | -70.1% | -29.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Senti Biosciences pay a dividend?
Not currently.
Is Senti Biosciences a good stock to buy?
We do not give buy or sell advice. Senti Biosciences scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.